• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, October 25, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Breast cancer studies ignore race, socioeconomic factors

Bioengineer by Bioengineer
June 27, 2018
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The Bloomberg School scientists, in a commentary that appears in the July issue of Cancer Causes & Control, point to evidence that social factors help determine people's vulnerability to cancer, and argue that these factors should be considered routinely in studies and risk assessments that bear on clinical care.

"We've been missing opportunities to understand and reduce disparities in breast cancer risk and outcomes," says lead author Lorraine T. Dean, ScD, an assistant professor in the Department of Epidemiology at the Bloomberg School. "Simply put, not enough is being done to understand how race, income level and other social factors tie in to cancer susceptibility."

A 2014 review of over 20 years of National Cancer Institute clinical trials, for example, found that only about 20 percent of the randomized controlled studies reported results stratified by race/ethnicity. In a follow-up analysis of 57 breast cancer observational and randomized controlled trials that were published in 2016, the researchers found that, after excluding those in which the primary focus was disparities, fewer than five percent of studies reported findings stratified by race or other socioeconomic factors.

As Dean and colleagues note in their commentary, it should be obvious that in general, neglecting race/ethnicity and other social factors in medical research can mask important drivers of bad outcomes. For example, a recent high-profile study sorting mortality rates by race and socioeconomic status revealed that midlife mortality is increasing among blue collar whites in the U.S. even though it is declining for the population overall. Those findings drew attention to ongoing increases in suicides and substance-abuse-related deaths for blue collar whites, and led researchers to zero in on economic despair and social decay as the likely causes.

"A lot of scientists don't want to deal with race or socioeconomic position in their studies because they think those characteristics aren't modifiable," Dean says. "But they can actually help identify factors that are modifiable. You can't change your genes, for example, but we still do genetic studies because they illuminate pathways we can change with medicines or other interventions."

Breast cancers are the principal research focus for Dean and colleagues. They see the potential–and many missed opportunities to date–for research to uncover or at least address social-related risk factors for this set of diseases.

They point out, for example, that standard breast cancer risk assessment tools haven't always taken race into account–even though there are significant racial disparities in the risks for certain types of breast cancer as well as breast cancer mortality rates. For many years, a commonly used questionnaire tool for assessing breast cancer risk (now known simply as the Breast Cancer Risk Assessment Tool) was validated only for white women. It tended to underestimate significantly the risks of breast cancers for black women, who have lower rates of mammogram screening and higher rates of breast cancer at younger ages. That error may have kept many black women from participating in cancer-prevention trials of drugs such as tamoxifen.

"The model was revised in 2015 to take race into account, and now estimates black female eligibility for chemoprevention at nearly three times the rate of the original model," says Dean.

Clinical trials and population studies should be powerful tools for uncovering links between social factors and cancer vulnerability, which in turn should lead to better risk reduction and/or treatment strategies. But here too, the necessary information isn't routinely gathered.

To address the issue, Dean and her colleagues recommend increasing education and awareness about the importance of inclusion of social factors in clinical research; adding requirements for data on social factors to journal guidelines for reporting study results; and refining cancer risk assessment tools by including social factors.

"If adopted, these measures would enable more effective design and implementation of interventions," Dean says, "and would help eliminate breast cancer racial and socioeconomic disparities by accounting for the social and environmental contexts in which cancer patients live and are treated."

"Social factors matter in cancer risk and survivorship" was written by Lorraine T. Dean, Sarah Gehlert, Marian L. Neuhouser, April Oh, Krista Zanetti, Melody Goodman, Beti Thompson, Kala Visvanathan, and Kathryn H. Schmitz.

Funding was provided by the National Institutes of Health (K01-CA184288, U54-CA155850, U01-CA116850, U54-CA155496, and P30-CA006973).

###

Media Contact

Barbara Benham
[email protected]
@JohnsHopkinsSPH

http://www.jhsph.edu

https://www.jhsph.edu/news/news-releases/2018/breast-cancer-studies-ignore-race-socioeconomic-factors.html

Share12Tweet8Share2ShareShareShare2

Related Posts

Assessing Quality of Life After Neoadjuvant Therapy

October 25, 2025

New FISH-Clinical Tool Predicts Bladder Cancer Survival

October 25, 2025

Unlocking Lactate’s Role in AML Prognosis

October 25, 2025

LAMB3 Expression Linked to Thyroid Cancer

October 25, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1281 shares
    Share 512 Tweet 320
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    309 shares
    Share 124 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    192 shares
    Share 77 Tweet 48
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    133 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Glymphatic Flow Dysfunction Linked to Parkinson’s Disease

Night Shift Impact on Nurses’ Heart Rate Variability

Assessing Quality of Life After Neoadjuvant Therapy

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.